STAMCAR: A Prospective EC-IC Bypass Registry

February 16, 2022 updated by: Lahey Clinic

A prospective registry evaluating the efficacy of EC-IC bypass in a subgroup of patients, specifically, patients with carotid occlusion and symptoms refractory to medical therapy and evidence for poor cerebrovascular reserve as evaluated by physiological testing (e.g. Diamox Challenge SPECT Scan). This subgroup includes:

  1. Hospitalized unstable patient with crescendo or postural TIA's
  2. Patients with multiple TIA's, limb-shaking TIA's, and/or cognitive decline despite medical therapy.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

The registry is a multi-center international prospective registry. The patients will be prospectively followed for 24 months. Enrollment into the registry will take place over 3 years.

The primary objective is to collect prospective data on cerebral revascularization via superficial temporal artery (STA) to middle cerebral artery (MCA) for symptomatic carotid occlusion patients to determine if the procedure can be performed with less than 8% major peri-operative benchmark.

The secondary objective is to determine if cerebral revascularization via STA to MCA bypass will improve cerebral hemodynamics, cognitive function, and quality of life in a defined subgroup of symptomatic carotid occlusion patients over a 2 year period.

Clinical outcome in terms of resolved symptomatology, improved cerebrovascular hemodynamics, and cognitive status will be assessed. Short term and long term follow-up for a period of 24 months will include assessment of ipsilateral stroke or TIA rate, mortality, graft patency, assessment of MCA and bypass flow rates (if available), cognitive evaluation and quality of life evaluation.

Following enrollment baseline demographics and operative data will be collected. Follow-up will be performed at 1 month (m), 3m, 6m, 12m and 24m. Occurrence of new TIA or stroke will be determined. The patient's bypass patency, Qualitative Magnetic Resonance Angiogram (QMRA) flow data (site discretion) and NIHSS Score (NIHSS), Barthel Index (mBARTHEL), modified Rankin Scales (mRANKIN), EuroQOL, and the Montreal Cognitive Assessment (MoCA) with digital Clock Drawing (dCDT) will be recorded. An additional battery of neurocognitive tests will also be administered (Symbol Digit Modalities Test SDMT, Delis-Kaplan Executive Function System D-KEFS and TRAILS A/B).

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Miami, Florida, United States, 33136
        • University of Miami
    • Illinois
      • Chicago, Illinois, United States, 60612
        • University of Illinois at Chicago
    • Massachusetts
      • Burlington, Massachusetts, United States, 01803
        • Lahey Hospital & Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with internal carotid artery or middle cerebral artery occlusion and symptoms refractory to medical therapy and evidence for poor cerebrovascular reserve as evaluated by physiological testing (e.g. Diamox Challenge SPECT Scan).

Description

Inclusion Criteria:

  • Internal carotid artery or middle cerebral artery occlusion
  • Transient ischemic attack (TIA) or ischemic stroke in the ipsilateral hemisphere within 30 days in patients who are either

    • hospitalized unstable patients with crescendo or postural TIA's, OR
    • Multiple TIA's, limb-shaking TIA's, and/or cognitive decline despite medical therapy*
  • Evidence of ipsilateral impaired cerebrovascular reserve on physiological testing (e.g. Diamox challenge SPECT)
  • Modified Rankin Score (mRS) >3
  • Language comprehension intact
  • Age 18-85 years * failure of medical therapy must include at least failure on a regimen of antiplatelets and statins.

Exclusion Criteria:

  • Moya-moya syndrome
  • Known heart disease likely to cause cerebral ischemia

    • Prosthetic Valves
    • Atrial Fibrillation
    • Infective endocarditis
    • Left atrial or ventricular thrombus
    • Sick sinus syndrome
    • Cardiac myxoma
    • Cardiomyopathy with ejection fraction < 25%
  • Any condition likely to lead to death within 2 years
  • Pregnancy
  • Allergy or contraindication to aspirin
  • Uncontrolled diabetes mellitus (FBS > 300 mg%/16.7 mmol/L)
  • Uncontrolled hypertension (systolic BP>180, diastolic BP >110), other than induced for control of pressure dependent symptoms
  • Uncontrolled hypotension (diastolic BP <65)
  • Unstable angina

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Patients with Ipsilateral Ischemic Stroke
Time Frame: During surgery
During surgery
Number of Patients with Ipsilateral Ischemic Stroke
Time Frame: Up to 30 days from surgery
Up to 30 days from surgery
Number of Patients that experience Stroke
Time Frame: After 30 days from surgery
After 30 days from surgery
Number of Patients that experience Death
Time Frame: After 30 days from surgery
After 30 days from surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cerebral Hemodynamic Testing
Time Frame: baseline, 3 months, 12 months
Steal, Reduced reserve, normal (specific modality to be determined by site)
baseline, 3 months, 12 months
Qualitative Magnetic Resonance Angiogram, Non-invasive Optimal Vessel Analysis Blood Flow Data
Time Frame: baseline, 3 months, 12 months
Site discretion; test assess the blood flow to the vessels in the brain
baseline, 3 months, 12 months
Bypass Patency
Time Frame: 3 months, 6 months, 12 months, 24 months
Blood flow remains normal through the bypass
3 months, 6 months, 12 months, 24 months
EuroQOL-5 Dimensions
Time Frame: baseline, 1 month, 3 months, 6 months, 12 months, 24 months
A standardized instrument for use as a measure of health outcomes and is applicable to a wide range of health conditions and treatments; provides a simple description profile and a single index value for health status.
baseline, 1 month, 3 months, 6 months, 12 months, 24 months
Montreal Cognitive Assessment (MoCA)
Time Frame: baseline, 1 month, 3 months, 6 months, 12 months, 24 months
The MoCA was designated as a rapid screening instrument for mild cognitive dysfunction; it assesses difference cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.
baseline, 1 month, 3 months, 6 months, 12 months, 24 months
National Institutes of Health Stroke Scale (NIHSS)
Time Frame: baseline, 1 month, 3 months, 6 months, 12 months, 24 months
A systematic assessment tool that provides a quantitative measure of stroke-related neurological deficit; used to evaluate acuity of stroke patients, determine appropriate treatment, and predict patient outcomes.
baseline, 1 month, 3 months, 6 months, 12 months, 24 months
Modified Rankin Scale (mRankin)
Time Frame: baseline, 1 month, 3 months, 6 months, 12 months, 24 months
A 6(0-5) point disability scale that is used widely in both secondary prevention and acute stroke trials, including most of the thrombolysis trials that ranks the patient based upon the disability symptoms
baseline, 1 month, 3 months, 6 months, 12 months, 24 months
Modified Barthel Index (mBarthel)
Time Frame: baseline, 1 month, 3 months, 6 months, 12 months, 24 months
The Barthel Index consists of 10 items that measure a person's daily functioning, specifically the activities of daily living and mobility. The items include feeding, moving from wheelchair to bed and return, grooming, transferring to and from a toilet, bathing, walking on level surface, going up and down stairs, dressing, continence of bowels and bladder. Can be used to monitor improvement in activities of daily living over time.
baseline, 1 month, 3 months, 6 months, 12 months, 24 months
Digital Clock Drawing Test (dCDT)
Time Frame: baseline, 1 month, 3 months, 6 months, 12 months, 24 months
The dCDT provides a novel technique to assess both cognitive and motor aspects of psychomotor speed within the same task and the potential to uncover subtleties of behavior not previously detected with non-digitized modes of data collection.
baseline, 1 month, 3 months, 6 months, 12 months, 24 months
Delis-Kaplan Executive Function System (D-KEFS)
Time Frame: baseline, 1 month, 3 months, 6 months, 12 months, 24 months
the D-KEFS Verbal Fluency Tests comprises of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures the examinee's ability to generate words fluently in an effortful, phonetic format (Letter Fluency), from overlearned concepts (Category Fluency), and while simultaneously shifting between overlearned concepts (Category Switching).
baseline, 1 month, 3 months, 6 months, 12 months, 24 months
Reitan Trails A/B Test
Time Frame: baseline, 1 month, 3 months, 6 months, 12 months, 24 months
Cognitive Assessment; assess the examinee's ability visual attention and task switching abilities; the trails should be made quickly as possible while trying to avoid mistakes.
baseline, 1 month, 3 months, 6 months, 12 months, 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Carlos David, MD, Lahey Hospital & Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2016

Primary Completion (Actual)

December 1, 2021

Study Completion (Actual)

December 1, 2021

Study Registration Dates

First Submitted

May 12, 2016

First Submitted That Met QC Criteria

May 19, 2016

First Posted (Estimate)

May 20, 2016

Study Record Updates

Last Update Posted (Actual)

March 4, 2022

Last Update Submitted That Met QC Criteria

February 16, 2022

Last Verified

August 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • LCID: 2015-034

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carotid Occlusion

Clinical Trials on EC-IC bypass

Subscribe